News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
